Securities code: 688298 securities abbreviation: Zhejiang Orient Gene Biotech Co.Ltd(688298) Announcement No.: 2022-002 Zhejiang Orient Financial Holdings Group Co.Ltd(600120) gene biological products Co., Ltd
Stock trading abnormal fluctuation announcement
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
Zhejiang Orient Financial Holdings Group Co.Ltd(600120) gene biological products Co., Ltd. (hereinafter referred to as “the company”) has accumulated 30% deviation from the closing price increase within three consecutive trading days (January 12, January 13 and January 14, 2022). According to the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock trading.
After the company’s self-examination and sent a letter to inquire about the controlling shareholders and actual controllers, as of the disclosure date of this announcement, there are no major matters that should be disclosed but not disclosed.
Market competition is fierce: in 2021, the company’s performance mainly depends on the sales performance of New Coronavirus antigen detection reagent (including home self testing) (COVID-19 antigen reagent) in the European market. On December 30, 2021, the company’s covid-19 antigen self-test reagent was designated by Siemens Healthcare (hereinafter referred to as “Siemens Healthcare”) authorized by the U.S. FDA and EUA. There are many suppliers of similar products in the market, which will face the risk of fierce market competition. As of the disclosure date of this announcement, it has no impact on the company’s operating performance. Whether the company’s future business performance can continue to maintain rapid growth is subject to major uncertainty, which mainly depends on the progress of global covid-19 epidemic prevention and control and the selection of covid-19 testing products by various countries, The company’s product market competitiveness and channel sales capacity (among them, the sales capacity of covid-19 antigen self-test reagent in the U.S. market mainly depends on Siemens Medical), as well as the company’s production capacity and the future development of conventional business.
1、 Details of abnormal fluctuations in stock trading
Within three consecutive trading days (January 12, January 13 and January 14, 2022), the deviation of the closing price increase has reached 30% in total. According to the trading rules of Shanghai Stock Exchange and the special provisions on stock trading on the science and Innovation Board of Shanghai Stock Exchange The relevant provisions of the detailed rules for real-time monitoring of abnormal stock trading on the science and Innovation Board of Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock trading.
2、 Relevant information concerned and verified by listed companies
According to the relevant regulations of Shanghai Stock Exchange, the company has made necessary verification on relevant issues, which is explained as follows: (I) production and operation
According to the company’s self-examination, the company’s current production and operation are normal without major changes; The market environment or industrial policies have not been significantly adjusted, production costs and sales have not fluctuated significantly, and the internal production and operation order is normal.
(II) major events
After the company’s self-examination and verification by letter to the controlling shareholder and actual controller of the company: as of the disclosure date of this announcement, except for the information publicly disclosed on the designated media, there are no major events affecting the abnormal fluctuation of the company’s stock trading price; There is no other major information that should be disclosed but not disclosed by the company, including but not limited to major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, business restructuring, asset stripping, asset injection, share repurchase, equity incentive, bankruptcy restructuring, major business cooperation, introduction of strategic investors and other major matters.
(III) media reports, market rumors and hot concepts
The company is concerned that the Citic Securities Company Limited(600030) Research Department released the covid-19 rapid detection plan launched in the United States, bred a new blue ocean for antigen detection and raised the target price on January 13, 2022, and made a profit forecast for the company’s performance from 2022 to 2023. In order to avoid misleading investors and safeguard the legitimate rights and interests of the company, the company hereby makes the following explanation: the report is only the opinions of the Citic Securities Company Limited(600030) research department, Does not represent the company’s position. The company has not provided relevant undisclosed operating performance data to the outside world; Nor has it made any business performance forecast from 2022 to 2023.
All information of the company is available on the website of Shanghai Stock Exchange (www.sse. Com. CN.) And the information published in the designated media. Please invest rationally and pay attention to investment risks.
(IV) other stock price sensitive information
After verification, the directors, supervisors, senior managers, controlling shareholders and actual controllers of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
3、 Statement of the board of directors and commitments of relevant parties
The board of directors of the company confirms that, except for the matters that have been disclosed in accordance with the provisions, the company does not have any matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of science and Innovation Board of Shanghai Stock Exchange or the planning and intention related to such matters, and the board of directors has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of science and innovation board Information that may have a great impact on the trading price of the company’s shares and their derivatives.
4、 Relevant risk tips
(I) risk of fierce market competition
In 2021, the company’s performance mainly depends on the sales performance of New Coronavirus antigen detection reagent (including family self testing) (COVID-19 antigen reagent) in the European market. On December 30, 2021, the company’s covid-19 antigen self-test reagent was designated by Siemens Healthcare (hereinafter referred to as “Siemens Healthcare”) authorized by the U.S. FDA and EUA. There are many suppliers of similar products in the market, which will face the risk of fierce market competition. As of the disclosure date of this announcement, it has no impact on the company’s operating performance.
Whether the company’s future business performance can continue to maintain rapid growth is subject to major uncertainty, which mainly depends on the progress of global covid-19 epidemic prevention and control and the selection of covid-19 testing products by various countries, The company’s product market competitiveness and channel sales capacity (among them, the sales capacity of covid-19 antigen self-test reagent in the U.S. market mainly depends on Siemens Medical), as well as the company’s production capacity and the future development of conventional business.
(II) secondary market fluctuation risk
The company specially reminds the majority of investors that due to the recent opening of covid-19 rapid detection reagent in the U.S. market, some enterprises have obtained FDA EUA product certification and relevant order expectations, the stock prices of relevant enterprises in the A-share covid-19 detection sector have risen sharply as a whole, and there is a risk of significant stock price fluctuation in the follow-up. Please invest rationally and pay attention to investment risks.
5、 Online announcement attachment
Reply to the inquiry letter on abnormal fluctuations in stock trading of Zhejiang Orient Financial Holdings Group Co.Ltd(600120) gene biological products Co., Ltd
It is hereby announced.
Board of directors of Zhejiang Orient Financial Holdings Group Co.Ltd(600120) gene biological products Co., Ltd
January 15, 2022
